CAR-T cell therapy for immune kidney disease
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of immune kidney disease (membranous nephropathy, IgA nephropathy, or ANCA vasculitis) that is hard to treat or has come back.
- Your kidney function and blood counts are within certain levels (doctor will check).
- You must not have active infections or other serious health conditions like heart disease or cancer.
- You and your partner must use birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
This trial tests a new CAR-T cell treatment for children and adults with steroid-resistant nephrotic syndrome (SRNS), a kidney condition that doesn't get better with standard medicines. The goal is to see if this therapy can help improve kidney function when other treatments have failed.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Hear when a new Relapsed/Refractory Immune Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.